CAMP antibody

Catalog No. ABIN487626

The Sheep Polyclonal anti-CAMP antibody has been validated for EIA. It is suitable to detect CAMP in samples from .

Quick Overview for CAMP antibody (ABIN487626)

Target: CAMP (cAMP) (Cyclic Adenosine Monophosphate (cAMP))

Reactivity: Please inquire

Host: Sheep

Clonality: Polyclonal

Conjugate: This CAMP antibody is un-conjugated

Application: Enzyme Immunoassay (EIA)

Product Details anti-CAMP Antibody

Purification: Ig Fraction

Immunogen: Cyclic AMP-BSA

Isotype: IgG

Application Details

Application Notes: ELISA: 6.05 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 6.05mg/mL (U.V. abs at 280nm)

Buffer: 20 mM Phosphate, 150 mM Sodium Chloride, pH 7.2 containing 0.09 % Sodium Azide as preservative

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Target Details for CAMP

Target: CAMP (cAMP) (Cyclic Adenosine Monophosphate (cAMP))

Alternative Name: cAMP / Cyclic AMP

Target Type: Chemical

Background: Cyclic adenosine monophosphate (cAMP) plays a key role as an intracellular second messenger for transduction events that follow a number of extracellular signals. The G-Protein Coupled Receptors (GPCR) is the largest family of cell surface receptors. They can be activated by different ligands, such as neurotransmitters, hormones, ions, small molecules, peptides, and other physiological signaling molecules. Typically, the binding of the ligands to its receptor resulting in the activation of G-proteins, in return, activates the effector adenylyl cyclase evoking the production of cAMP. The activation of a protein kinase by cAMP results in the phosphorylation of substrate proteins. Currently successful drugs in marketing have been developed to target these receptors. Among the GPCRs, ~367 receptors are potential drug development targets, but only about 20 have been used to generate therapeutically and commercially successful drugs so far. Because the involvement of cAMP can amplify the response of the ligand binding, the second messenger cAMP has been largely employed to monitor the activation of the GPCR to facilitate the therapeutic drug discovery.

Pathways: Cellular Response to Molecule of Bacterial Origin